10-Q: Aligos Therapeutics Reports Q1 2025 Financial Results, Driven by Warrant Valuation Change

Aligos Therapeutics reports a net income of $43.1 million for Q1 2025, primarily due to a significant gain from the change in fair value of common warrants, while highlighting progress in its clinical development programs.

Summary

• Aligos Therapeutics reported a net income of $43.1 million for the three months ended March 31, 2025, compared to a net loss of $34.9 million for the same period in 2024.
• The significant increase in net income was primarily driven by a $61.5 million gain from the change in fair value of the 2023 common warrants.
• Revenue from customers decreased to $0.3 million in Q1 2025 from $0.7 million in Q1 2024, due to the near completion of the original agreement with Amoytop.
• Research and development expenses decreased by $1.9 million to $14.5 million in Q1 2025, mainly due to reduced clinical study costs in the MASH program.
• General and administrative expenses decreased by $1.6 million to $5.1 million in Q1 2025, primarily due to reduced third-party expenses and employee-related costs.
• The company's cash, cash equivalents, and investments totaled $137.9 million as of March 31, 2025.
• Aligos expects its existing cash, cash equivalents, and investments will fund operations for at least the next 12 months.
• The Phase 2 B-SUPREME study for ALG-000184 is expected to begin in mid-2025 with interim data projected in 2026 and topline data anticipated in 2027.

Sentiment

Score: 7

Explanation: The document presents a mixed sentiment. While the company reports a net income, it's largely due to a non-operational factor (warrant valuation). The progress in clinical trials and strong cash position are positive, but the company still faces significant risks and competition.

Positives

• The company achieved a net income of $43.1 million in Q1 2025, driven by a significant gain from the change in fair value of common warrants.
• Aligos has a strong cash position of $137.9 million, expected to fund operations for at least the next 12 months.
• ALG055009 demonstrated statistically significant reductions in liver fat in a Phase 2a trial.
• ALG097558 has shown promising potency against SARS-CoV-2 variants.
• The FDA cleared the IND for a Phase 1 drug-drug interaction study for ALG-000184.

Negatives

• Revenue from collaborations decreased significantly due to the termination of a collaboration agreement.
• Revenue from customers decreased by $0.4 million for the three months ended March 31, 2025, when compared to the same period in 2024.
• The company has a history of net losses and negative cash flows from operations.

Risks

• The company is dependent on the successful development of its drug candidates, which is subject to numerous risks and uncertainties.
• Clinical trials are expensive and can take many years to complete, and their outcomes are inherently uncertain.
• The company faces significant competition from other pharmaceutical and biotechnology companies.
• The company's ability to raise additional funds depends on financial, economic and other factors, many of which are beyond its control.
• The company is subject to various U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, violations of which can have serious negative consequences for its business.

Future Outlook

Aligos expects its existing cash, cash equivalents, and investments will enable it to fund its operations for at least the next 12 months. The Phase 2 B-SUPREME study for ALG-000184 is expected to begin in mid-2025 with interim data projected in 2026 and topline data anticipated in 2027.

Management Comments

• The Aligos team has a demonstrated track record of success in drug development and medicinal chemistry in liver and viral diseases, resulting in three potential bestinclass drug candidates.

Industry Context

Aligos is operating in a competitive landscape with major pharmaceutical companies and biotechnology firms also developing treatments for chronic HBV infection, MASH, and coronaviruses. The company is focusing on developing differentiated drug candidates with enhanced pharmacologic properties to compete effectively.

Comparison to Industry Standards

• ALG000184 treatment may be superior to NAs in HBeAg +/subjects in achieving HBV DNA levels < LLOQ after 48 weeks on treatment, which is the approvable endpoint for chronic suppressive therapy in chronic HBV infection compared to Phase 3 studies with the current standard of care nucleos(t)ide analogs (NAs), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF).
• ALG-055009 has been purposefully designed to exhibit significantly greater potency (approximately 50-fold higher compared to resmetirom in head-to-head in vitro studies) and enhanced selectivity, along with optimized pharmacologic properties to deliver an improved PK profile.
• ALG097558 has been shown to be at least 3-fold more potent than nirmatrelvir and other PIs in clinical development against a panel of SARS-CoV-2 variants.

Corporate Governance

Legal Proceedings

• From time to time, we may become involved in litigation or other legal proceedings. While the outcome of any such proceedings cannot be predicted with certainty, we are not currently involved in any legal proceedings that we believe are, individually or in the aggregate, material to our business, results of operations or financial condition.

Stakeholder Impact

• Shareholders: The net income and progress in clinical trials could positively impact shareholder value.
• Employees: Continued funding and development programs provide job security and growth opportunities.
• Patients: Advancing drug candidates offer potential new treatments for chronic HBV infection, MASH, and coronaviruses.
• Collaborators: Continued collaboration and licensing agreements provide opportunities for partnerships and revenue generation.

Next Steps

• Continue clinical development of ALG-000184, ALG055009, and ALG-097558.
• Initiate the Phase 2 B-SUPREME study for ALG-000184 in mid-2025.
• Assess potential Phase 2b clinical trial study designs for ALG055009.
• Seek additional external funding for the ALG097558 program.
• Continue Phase 2 enabling activities for ALG055009, with expected completion in the middle of 2025.

Key Dates

Keywords

Aligos Therapeutics, Financial Results, Clinical Trials, ALG-000184, ALG055009, ALG-097558, Hepatitis B, MASH, Coronavirus, Warrants, Biotechnology